Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Background: PD-L1 expression as measured by the SP142 PD-L1 IHC assay is associated with improved efficacy with atezo in patients with NSCLC, including overall survival. In capturing PD-L1 on both tumor cells (TC) and tumor-infiltrating immune cells (IC), this assay is able to determine preexisting immune status, underscoring the predictive value of PD-L1 IHC.
Background: In patients (pts) with NSCLC, the efficacy of atezo (anti-PDL1) correlates with PD-L1 expression on tumor cells (TC) and tumor-infiltrating immune cells (IC). We further examined the association between tumor mutation load (ML) and efficacy of atezo in pts with NSCLC.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.